Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The funds will be used to scale up existing operations and launch new products
Rad-G is a rugged, portable, handheld Masimo SET Measure-through Motion and Low Perfusion pulse oximeter and noninvasive respiration rate monitor
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
It is estimated that one-third of our country’s population has some form of these disorders
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Subscribe To Our Newsletter & Stay Updated